-
Recent Posts
- Late-Life Depression: Prevalence and Treatment Considerations (JGCR)
- Babylon Health Applies Artificial Intelligence to Improving Integration of Care and Population Health in Wolverhampton (HTN / RWT / BMJ / Lancet / NHS England)
- Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
- Dementia-Related Hospital Admissions (BBC News / Alzheimer’s Society)
- NHS Demands Action to Reduce Betting-Related Ill Health (BBC News / NHS England / Respublica)
Archives
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Pfizer Inc.
A Further Set-Back for Progress in Dementia Drug Development? (BBC News)
Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding
|
Leave a comment
Dementia Discovery Fund Launched (WDC / ARUK)
Summary The Dementia Discovery Fund (DDF) was launched on October 21st 2015. Full Text Link Reference Launch of Dementia Discovery Fund. London [Online]: World Dementia Council (WDC), November 10th 2015. See also: Full Text Link Reference $100m Dementia Discovery Fund … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Andrew Plump: Chief Medical and Scientific Officer at Takeda Pharmaceutical Company Limited, ARUK: Alzheimer’s Research UK, Big Pharma, Biogen, Biopharmaceutical Companies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Jan Lundberg: President of Lilly Research Laboratories, Dr Matthew Norton: Alzheimer's Research UK, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, GSK Johnson & Johnson, International Collaborations, International Programmes, Jane Ellison, Johnson & Johnson, Lilly, Mikael Dolsten: President of Worldwide Research and Development at Pfizer, Partnership, Partnership and Collaboration, Partnership Working, Patrick Vallance: President of Pharmaceuticals R&D at GSK, Paul Stoffels: Worldwide Chairman of Johnson & Johnson, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding, SV Life Sciences, SV Life Sciences (SVLS), Takeda, WDC: World Dementia Council, World Dementia Council
|
Leave a comment
Announcements From WHO’s First Ministerial Conference on Global Action Against Dementia Conference (Dementia Challenge / Department of Health / World Dementia Council / WHO / GAAD)
Summary Health Secretary Jeremy Hunt has announced a $100 million Dementia Discovery Fund at the World Health Organisation’s First Ministerial Conference on Global Action Against Dementia Conference. The Dementia Discovery Fund will be used to finance dementia research with the … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Awareness Raising, Big Pharma, Biogen, Biopharmaceutical Companies, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Discovery Fund, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, Former Health Secretary Jeremy Hunt, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Johnson & Johnson, JP Morgan, Knowledge Translation, Leadership, Lilly, Ms. Cathrin Petty: JP Morgan, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Pfizer, Pfizer Inc., Pharmaceutical Industry, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Prevention of Dementia (ILC-UK)
Summary This International Longevity Centre – UK (ILC-UK) report summarises current knowledge about how more can be done to prevent the scale of dementia prevalence in future, and to reduce avoidable costs. It considers the potential savings achievable by tackling … Continue reading →
Posted in Charitable Bodies, Commissioning, Community Care, Depression, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Practical Advice, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Active Ageing, Age and Ageing, Ageing and Dementia, Ageing Population, Alcohol and Drug Consumption, Alcohol Consumption, Alcohol Misuse, Alzheimer’s Disease: Prevalence, Australian National Dementia Strategy, Awareness Campaigns, Baroness Sally Greengross (APPG on Dementia), Behavioural Pathways to Health Inequalities, Behavioural Risk Factors and Dementia, Blood Pressure, Burden of Alzheimer’s Disease, Burden of Dementia, Cumulative Benefit of Reducing Risk Factors, Dementia Policy, Dementia Risk Prevention, Dementia Risk Reduction, Dementia: a Public Health Priority, Diabetes Mellitus, Diet and Dementia, Dietary Factors, Disability Dementia and Frailty in Later Life: Mid-Life Interventions, Disease Burden, Eating and Drinking, Education and Awareness, Epidemiology, Epidemiology and Statistics, Financial Constraints, Financial Pressures, Health Inequalities, Health Inequalities in England, Health Policy, Healthy Ageing, Healthy Behaviours, Healthy Communities, Healthy Lifestyles, Healthy Living, Hypertension, ILC-UK: International Longevity Centre UK, Incidence of Alzheimer’s Disease, Integrated Prevention Approaches, International Longevity Centre, International Longevity Centre UK, International Longevity Centre UK (ILC-UK), International Longevity Centre UK (ILCUK), Life-Course Approach to Healthy and Active Ageing, Lifestyle Risk Factors, Midlife Hypertension, NHS Finances, Obesity, Obesity Risk, Obesity Time-Bomb, Pfizer Inc., Physical Activity, Physical Activity and the Environment, Physical Inactivity, Policy and Law, Prevalence, Prevalence of Dementia, Preventing Type 2 Diabetes, Prevention, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention Approaches, Prevention of Dementia, Prevention Programmes, Preventive Care, Preventive Services, Primary Preventative Strategies, PSSRU: Personal Social Services Research Unit (LSE), Psychosocial Protective and Risk Factors, Public Awareness, Public Health, Public Health Interventions, Reducing the Incidence of Dementia, Risk Factors, Risk Factors for Alzheimer's Diseease, Savings in Private Payments and Informal Care, Secondary Preventative Strategies, Sedentary Behaviour, Sleep Disorders, Smoking, Social Determinants of Health Inequalities, Socio-Economic Patterning, Staying Healthy for Longer, Successful Ageing, Type 2 Diabetes, Type 2 Diabetes: Prevention, Unhealthy Behaviours, Unhealthy Lifestyles, Unhealthy Living
|
Leave a comment
G8 Dementia Summit to Coordinate Global Efforts on Dementia Research (Department of Health)
Summary The UK is planning to use its Presidency of the G8 to coordinate a more international approach to dementia research. UK annual funding on dementia research is increasing to £66 million by 2015, and President Obama has committed the US to spending around … Continue reading →
Posted in Department of Health, For Researchers (mostly), In the News, International, National, Quick Insights, UK, Universal Interest
|
Tagged Barack Obama, Baxter, Challenge on Dementia (David Cameron), Covance, David Cameron, Dementia Research, G8 Dementia Summit, Global Burden of Disease Study, Global Context, Global Outlook, International Organisations, International Programmes, Johnson & Johnson, OECD, Organisation for Economic Co-operation and Development (OECD), Pfizer, Pfizer Inc., Prime Minister’s Challenge on Dementia: Annual Report (2013), Prime Minister’s Dementia Challenge, Research and Development, Research and Innovation, Research Commitment, Research Mapping, Research Networks, Translational Research, UK Research Strengths in Dementia, World Alzheimer Report 2010
|
Leave a comment
Bapineuzumab: Alzheimer’s Drug Trials Halted (Healthcare Today UK)
Summary Two U.S. drug companies have halted trials of bapineuzumab, an experimental drug to treat Alzheimer’s Disease. The drug failed to produce any improvement in the symptoms of dementia sufferers. Pfizer Inc. and Johnson & Johnson had been testing bapineuzumab, which had been designed … Continue reading →
Posted in For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Alzheimer's Gene (APOE4 Gene), APOE4 Gene, Bapineuzumab, Eli Lilly, Experimental Alzheimer's Drugs, Healthcare Today UK, Johnson & Johnson, Pfizer Inc., Solanezumab (Eli Lilly), Tau, Tau Protein
|
Leave a comment
